Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

1000 patients were successfully recruited by the Prospective Cohort for Early Detection of Liver Cancer (Pearl) clinical study. This study has been developed to recruit patients with cirrhosis who are known to be at high risk for liver cancer.

Pearl was developed to recruit patients with cirrhosis who are known to be at high risk for liver cancer. The study aims to recruit 3000 people with liver cirrhosis, of which 1000 have been recruited to date. The patients were recruited from 40 hospital sites across the UK. Pearl has been developed to recruit patients with cirrhosis who are known to be at high risk for liver cancer. It is a key clinical study in the Cancer Research UK funded DeLIVER programme that aims to use new technologies for liver cancer risk prediction and detection.

Patients in the Pearl study may have liver cancer caused by hepatitis virus B or C, alcohol or obesity. These participants show a higher risk of developing liver cancer and will be monitored over time to identify the earliest detectable indications of liver cancer and to develop new prediction models for the individual risk of liver cancer development. A proportion of participants have already been diagnosed with HCC since enrolment in the study providing invaluable data and samples.

The Cancer Research UK funded DeLIVER programme led by Professor Eleanor Barnes, Professor of Hepatology and Experimental Medicine at NDM’s Experimental Medicine Division, aims to overcome the barriers to the early detection of Hepatocellular cancer (HCC) by characterising the pre-cancerous liver microenvironment and measuring this by applying new methodologies in a range of disciplines. By establishing an internationally renowned research team with expertise in the fields of immunology, imaging, (epi)genomics, biochemistry, oncology and integrative data science, the DeLIVER programme looks to target the early detection of HCC and improve patient survival.

Read more about the DeLIVER programme and the team organising the Pearl clinical study by visiting the DeLIVER website.

Similar stories

OUCRU partner hospital receives Viet Nam medical achievement award

Oxford University Clinical Research Unit’s host and partner in Ho Chi Minh City, the Hospital for Tropical Diseases, was recently honoured with the Vietnam 2023 Medical Achievement Award at an event hosted by Voice of Ho Chi Minh City (VoH).